P009 Hidradenitis Suppurativa: Case-Based Clinical Pearls
DESCRIPTION
Challenging cases of hidradenitis suppurativa will be presented in an interactive format, including but not limited to management of HS in the setting of pregnancy, comorbidities such as chronic infections and malignancy, and therapeutic failure. Discussion topics include how to approach layering therapy, multi-biologic failure, and therapeutic drug monitoring. HS procedures that a dermatologist can perform in their office will be outlined. Flare and pain management strategies will also be discussed. This symposium will provide tips to the practicing dermatologist on how to deal with challenging patient situations that are relevant to real-life practice.
LEARNING OBJECTIVES
Utilize up-to-date evidence to approach challenging scenarios in HS management using a case-based format and addressing comorbidities, treatment selection, recalcitrant disease, and pregnancy.
Identify strategies to manage HS flares.
Describe procedures that can be done in the outpatient setting for patients with HS.
SCHEDULE
8:00 PM
Procedures you can do in your office for HS
Maria Aleshin, MD, FAAD
8:20 PM
Recalcitrant HS: What to do next?
Jennifer Lin Hsiao, MD, FAAD
8:40 PM
Treating HS in the setting of malignancy and chronic infections
Steven Daniel Daveluy, MD, FAAD
9:00 PM
Biologic switching and therapeutic drug monitoring
Alexandra P Charrow, MD, FAAD
9:20 PM
HS flare management
Natalie Fragoso, MD, FAAD
9:40 PM
Approach to pregnant HS patients
Katrina Lee, MD, FAAD
9:55 PM
Non-pharmacological approaches to HS
Vivian Shi, MD, FAAD
10:10 PM
Challenging cases panel
10:40 PM
Q&A Discussion
SPEAKERS
Maria Aleshin, MD, FAAD
Alexandra P Charrow, MD, FAAD
Brigham and Women's Hospital and Harvard Medical School
Steven Daniel Daveluy, MD, FAAD
Wayne State University
Natalie Fragoso, MD, FAAD
Jennifer Lin Hsiao, MD, FAAD
Katrina Lee, MD, FAAD
Vivian Shi, MD, FAAD
University of Washington, Seattle, WA
HANDOUTS
SPEAKER DISCLOSURES
Maria Aleshin, MD, FAAD
Mirador – Consultant (1099 relationship)(No Compensation Received); Novartis – Advisory Board(Fees); Santa Ana Bio – Consultant (1099 relationship)(Fees); UCB – Other(Grants/Research Funding);
Alexandra P Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Steven Daniel Daveluy, MD, FAAD
AbbVie – Speaker(Honoraria); Incyte – Advisory Board(Honoraria); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Natalie Fragoso, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Acelyrin – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); Target-Derm – Investigator(Grants/Research Funding); UCB Pharma – Consultant (1099 relationship)(Fees);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Consultant(Fees), Speaker(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Katrina Lee, MD, FAAD
No financial relationships exist with ineligible companies.
Vivian Shi, MD, FAAD
AbbVie – Advisory Board(Fees), Speaker(Fees); Alumis – Advisory Board(Honoraria); Aristea Therapeutics – Advisory Board(Fees); Bain Capital – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Advisory Board(Fees); Burt's Bees – Consultant(Fees); Ceraclere – Consultant (1099 relationship)(Fees); Dematology Foundation – Other(Grants/Research Funding); Demira – Advisory Board(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees); Eli Lilly and Company – Advisory Board(Fees); Foundation of Atopic Dermatitis – Other(Grants/Research Funding); Galderma – Advisory Board(Fees); Genentech, Inc. – Advisory Board(Honoraria); Global Parents for Eczema Research – Consultant(No Compensation Received); GpSkin – Consultant(Fees); HS Foundation – Board of Directors(No Compensation Received); Incyte – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); LearnHealth/LearnSkin – Other(Fees), Stockholder(Stock); Leo Pharma – Consultant (1099 relationship)(Fees); Menlo Therapeutics – Advisory Board(Fees); National Eczema Association – Consultant (1099 relationship)(Honoraria), Speaker(No Compensation Received); Novartis – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees); Polyfins, Inc – Consultant (1099 relationship)(Fees); Regeneron – Speaker(Fees); Sanofi Genzyme – Advisory Board(Fees), Speaker(Fees); Skin Actives Scientific – Other(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees); UCB Pharma – Advisory Board(Honoraria);